News | April 22, 2024
Vertex announces advancements of Suzetrigine in acute and neuropathic pain
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Around 7% of the Indian population suffers from IBS
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Sun Pharma's Dadra facility receives OAI status from US FDA
A significant proportion of healthcare professionals still tend to favor branded drugs
Subscribe To Our Newsletter & Stay Updated
